论文部分内容阅读
目的观察非酒精性肝硬化合并乙型肝炎病毒感染患者应用阿德福韦酯治疗效果及对预后的影响。方法 72例非酒精性肝硬化合并乙型肝炎病毒感染患者随机分为观察组和对照组各36例,观察组在对照组常规治疗基础上口服阿德福韦酯,1次/d,10mg/次,疗程为1a。比较2组患者治疗效果及预后。结果 2组患者治疗后血清总胆红素、谷丙转氨酶、凝血酶原时间均较治疗前降低(P<0.05),血清白蛋白较治疗前升高(P<0.05),观察组上述指标较对照组改善更明显(P<0.05);观察组总有效率(91.7%)高于对照组(77.8%)(P<0.05)。结论阿德福韦酯治疗非酒精性肝硬化合并乙型肝炎病毒感染效果好,可有效改善患者肝功能。
Objective To observe the effect of adefovir dipivoxil treatment and prognosis in patients with non-alcoholic cirrhosis and hepatitis B virus infection. Methods Seventy-two patients with non-alcoholic cirrhosis and hepatitis B virus infection were randomly divided into observation group (36 cases) and control group (36 cases). The observation group was given adefovir dipivoxil once daily, 10 mg / Times, treatment for 1a. The treatment effect and prognosis of two groups were compared. Results Serum total bilirubin, alanine aminotransferase, and prothrombin time were lower in both groups (P <0.05) and serum albumin (P <0.05) after treatment than those before treatment The improvement in the control group was more obvious (P <0.05). The total effective rate in the observation group (91.7%) was higher than that in the control group (77.8%) (P <0.05). Conclusion adefovir dipivoxil treatment of non-alcoholic cirrhosis with hepatitis B virus infection is effective, can effectively improve liver function in patients.